about
When to start antiretroviral therapy in children aged 2-5 years: a collaborative causal modelling analysis of cohort studies from southern AfricaVirologic response in children treated with abacavir-compared with stavudine-based antiretroviral treatment: a South African multi-cohort analysisAntiretroviral therapy outcomes in HIV-infected children after adjusting protease inhibitor dosing during tuberculosis treatment.Tuberculosis Immune Reconstitution Inflammatory Syndrome in children initiating Antiretroviral Therapy for HIV infection: A systematic literature reviewEarly mortality and loss to follow-up in HIV-infected children starting antiretroviral therapy in Southern Africa.Six-month gain in weight, height, and CD4 predict subsequent antiretroviral treatment responses in HIV-infected South African children.Virologic failure and second-line antiretroviral therapy in children in South Africa--the IeDEA Southern Africa collaboration.Temporal trends in the characteristics of children at antiretroviral therapy initiation in southern Africa: the IeDEA-SA CollaborationPrognosis of children with HIV-1 infection starting antiretroviral therapy in Southern Africa: a collaborative analysis of treatment programsAntiretroviral therapy responses among children attending a large public clinic in Soweto, South Africa.The contribution of maternal HIV seroconversion during late pregnancy and breastfeeding to mother-to-child transmission of HIV.Nevirapine versus ritonavir-boosted lopinavir for HIV-infected children.Variability of growth in children starting antiretroviral treatment in southern Africa.Predictors of loss to follow-up among children in the first and second years of antiretroviral treatment in Johannesburg, South Africa.Challenges to pediatric HIV care and treatment in South Africa.Accuracy of immunological criteria for identifying virological failure in children on antiretroviral therapy - the IeDEA Southern Africa CollaborationThe role of targeted viral load testing in diagnosing virological failure in children on antiretroviral therapy with immunological failure.Effects of rifampin-based antituberculosis therapy on plasma efavirenz concentrations in children vary by CYP2B6 genotype.Effect on mortality and virological response of delaying antiretroviral therapy initiation in children receiving tuberculosis treatmentMicrobiological investigation for tuberculosis among HIV-infected children in Soweto, South Africa.The effect of early initiation of antiretroviral treatment in infants on pediatric AIDS mortality in South Africa: a model-based analysis.Frequency of stavudine substitution due to toxicity in children receiving antiretroviral treatment in sub-Saharan Africa.Effect of baseline immune suppression on growth recovery in HIV positive South African children receiving antiretroviral treatment.Cost and outcomes of paediatric antiretroviral treatment in South Africa.HAART and risk of tuberculosis in HIV-infected South African children: a multi-site retrospective cohort.Potent and Sustained Antiviral Response of Raltegravir-based Highly Active Antiretroviral Therapy in HIV Type 1-infected Children and Adolescents
P50
Q28535251-DBCF68A8-BD63-4E95-8774-F96915B1A773Q33624953-918227C8-00B6-47B8-BCCC-2DAE43D6A990Q33839294-C90388EB-8157-499B-9B44-6C37FAB4AD70Q34003099-BB3A38AE-BD9A-484E-9D76-71B13876F30EQ34077664-9DDF561F-9845-4099-AD73-A37BE7583FF3Q34129589-57FB75CB-9DC7-48AC-9BE5-87BBCD1B7E37Q35014160-22CDA23B-73C3-44E3-9EC5-9804DD4A377BQ35074354-135C48B7-9CA4-4235-8C0D-99B8DC7AF6CCQ35148237-BDAF71B4-94C3-4BC6-B6BC-18ADCD156A77Q35350315-556E0C4E-1F23-4208-8A62-7FDBF9504B52Q36043393-567C81CF-1117-4231-A1C3-2059DE15F55EQ36238419-E1D65B15-88A4-4E44-A4EF-DDCEDA56E490Q36277597-52381106-61BC-467B-804A-F0E5BF655093Q36566897-EFB77B53-4C3C-4FDF-B6BB-F62520DC0B76Q37053018-8B6FBDAE-D43C-48CD-AFAE-74DD09AF2FBBQ37199247-24B100C9-38BA-4173-991B-9DFF10B5A9D1Q37315991-AAAD1411-6DEE-4E5F-AAA7-51805891E041Q37429325-42E7690C-3451-4EB7-AFFD-193928BBE8E3Q37509463-003EF13D-284E-4CD3-BB7B-D14D028A55C2Q42211837-B30B737F-B72D-4640-B85F-517301C131DDQ44434681-766CFB27-3638-4FDF-9BEC-220EB34C1706Q46296295-1B7609E6-B8FA-4A8F-AA02-89745C7C5FE0Q46451668-120F1018-A89F-4D25-ABA0-AD104DFE9123Q46487268-049554B1-3091-4116-9E29-E830C8EB695EQ51630083-C21ACF2E-4FD0-4054-A3C7-9233C409432EQ56835968-4608749B-8EA0-445A-8766-2B5742F042AF
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Harry Moultrie
@ast
Harry Moultrie
@en
Harry Moultrie
@es
Harry Moultrie
@nl
Harry Moultrie
@sl
type
label
Harry Moultrie
@ast
Harry Moultrie
@en
Harry Moultrie
@es
Harry Moultrie
@nl
Harry Moultrie
@sl
prefLabel
Harry Moultrie
@ast
Harry Moultrie
@en
Harry Moultrie
@es
Harry Moultrie
@nl
Harry Moultrie
@sl
P106
P21
P31
P496
0000-0001-9722-0699